© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Syndicated Loans

More articles

More articles

More articles

  • Pfizer has agreed to buy US compatriot Array Biopharma for around $11.4bn in enterprise value in a heavily debt-driven acquisition. This has led to warning shots from the rating agencies.
  • Vue International’s revamped refinancing has tightened doc terms and pricing at the same time, ahead of commitments later on Tuesday, making it harder for part-owner Omers to take money out through its sub-debt —while also narrowing the OID and testing tighter pricing. The issuer may also include a sterling carve-out.
  • The European Leveraged Finance Alliance has prepared a questionnaire on deal covenants, to help investors grill arrangers and issuers at roadshow meetings, circulating the standard question list to the market’s big investment banks, as well as to its investor members.
  • Singapore’s Marina Bay Sands is seeking a total of S$4bn ($2.9bn) from the loan market, while also planning to extend its 2012 borrowing.
  • FRANKFURT PRIVATE DEBT ROUNDTABLE The Schuldschein market has kept up its momentum across Europe and elsewhere, but two regions have been curiously quiet. Iberia and Italy have implied investment grade borrowers well suited to the market, yet only a few have been tempted to use it. Are there barriers to entry and how can they be overcome?
  • Europe’s private debt markets are progressing admirably. More and more companies are issuing, or at least aware of the possibility — and they have a varied choice of markets. Players in the Schuldschein and US PP markets are confident and looking ahead to new opportunities, as the products grow in geographical reach, asset class and technique. As Jon Hay reports, there’s just one snag — the credit cycle is nearing its end.